@article{article, keywords = {Onchocerciasis, Ivermectin, Coverage, Adherence, Systematic review, Meta-analysis, Cameroon}, author = {Nditanchou R and Minkat T and Djeunga H and Selby R and Kamgno J and Verhoeven V and Colebunders R and Fodjo J}, title = {Ivermectin Mass Drug Administration Coverage Against Onchocerciasis in Cameroon, 2000{\textendash}2025: A Systematic Review and Meta-analysis}, abstract = {

Background

Persistent onchocerciasis transmission has been documented in some Cameroonian foci despite long-term ivermectin mass drug administration (MDA). We synthesized treatment coverage, adherence and determinants.

Methods

We systematically reviewed seven databases and grey literature (2000{\textendash}2025). District-year coverage observations were standardized to total-population epidemiological coverage and pooled using logit-transformed random-effects meta-analysis with Restricted Maximum Likelihood estimation and study/district cluster-robust inference. Adherence, infection prevalence and barriers to treatment were described separately.

Results

Thirty-two studies/reports were included among which 20 independent sources contributed 116 observations to the primary meta-analysis. Standardized survey coverage averaged 66.5\% (range 32.0{\textendash}88.3\%); 45/116 (38.8\%) observations were below the 65\% recommendation. Programme-reported coverage exceeded survey estimates in 97/98 paired observations by a mean 21.7 percentage points. Pooled coverage was 67.3\% (95\% CI 65.0{\textendash}69.5\%; I{\texttwosuperior}=98.5\%; prediction interval 40.6{\textendash}86.1\%); the cluster-robust 95\% CI was 56.8{\textendash}76.3\%. Five-year adherence ranged from 24\% to 67\%, while systematic non-adherence ranged from 6.8\% to 35\% across reported settings. Qualitative synthesis identified setting-specific combinations of missed contact, absence, distribution failures, refusal or hesitancy, adverse-effect concerns, information and trust barriers, mobility and temporary ineligibility. Microfilarial prevalence declined substantially from baseline (52\% to 95\%) but remained highly heterogeneous across long-treated settings, with the latest reported post-CDTI prevalence ranging from 0\% to 47.0\%.

Conclusions

Ivermectin mass drug administration (MDA) coverage in Cameroon was highly heterogeneous, mirroring variations in infection prevalence. Programme-reported coverage consistently exceeded survey-based estimates. Coverage gaps reflected context-specific operational and community acceptance barriers. Elimination monitoring should therefore triangulate survey-based coverage and adherence, local delivery barriers, and transmission indicators to guide targeted programme improvements and onchocerciasis elimination decisions.

}, year = {2026}, journal = {International Journal of Infectious Diseases}, pages = {1 - 41}, month = {10/2026}, publisher = {Elsevier BV}, issn = {1201-9712}, url = {https://www.sciencedirect.com/science/article/pii/S1201971226008477/pdfft?md5=2d8eb95cce08abf66cabbdc379bf5da0\&pid=1-s2.0-S1201971226008477-main.pdf}, doi = {10.1016/j.ijid.2026.109212}, language = {ENG}, }